Yuhan acquires new drugs from biotech venture firms
By Chon, Seung-Hyun
24.07.31 12:07:16
°¡³ª´Ù¶ó
0
Q2 R&D cost 40%¡è YoY¡¦reaching the highest amount in the past 5 years
Invested KRW 8 billion in two biotech ventures¡¦paid technology fees for acquiring promising new drugs
In search of new opportunities through outward investment
Yuhan significantly increased its research and development (R&D) investment. Over the past five years since acquiring new drug technology from biotech venture companies, Yuhan's R&D investment size has reached its peak. This expansion of outward investment seems to be the company's outlook for securing a new portfolio.
According to Yuhan on July 31st, the company's R&D cost in Q2 amounted to KRW 53.5 billion, up 39.8% from KRW 38.2 billion year over year (YoY). It increased 17.0% from the previous quarterly investment amount of KRW 45.7 billion.
Yuhan's quarterly R&D investment amount exceeded KRW 50 billion in four years since Q4 2020. In 2020, its R&D investment spending significantly incr
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)